There is no time like spring with its milder temperatures to get re-energized and become more committed to your health through exercise and nutrition.
Shire recently announced that the FDA has approved VONVENDI® for perioperative management of bleeding in adults with VWD.
Emicizumab-kxwh (HEMLIBRA, Genentech) was approved for use by the US Food and Drug Administration on November 16, 2017 for individuals with hemophilia A and inhibitors.
NHF's MASAC has issued the latest revision to their most comprehensive treatment document.
The designation is for people with hemophilia A without inhibitors.
ICER is an independent and non-partisan research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare and healthcare delivery innovations.
The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B.
Applications are now open! The selected KCS recipient will receive an award of $1,000 toward their tuition costs.
Updated statement from Genentech on Hemlibra, March 28, 2018.
The screening kit was developed for broad utility for both laboratories seeking a standardized inhibitor assay for clinical management and multi-center clinical studies of patients with hemophilia A
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car